Tag: Journal of Wound Care

Journal of Wound Care – July issue available online

Research and best practice – all in one resource
Wound Central is a specialist publication from Journal of Wound Care, for healthcare professionals across North America involved in skin integrity and wound management. It shares the latest clinical best practice, peer-reviewed research and medical education, brought to you with the support of the following associations:

  • American Vein and Lymphatic Society (AVLS)
  • Association for the Advancement of Wound Care (AAWC)
  • Academy of Physicians in Wound Healing (APWH)
  • Wound Care Education Institute (WCEI)

July issue is available now. Register here to read the latest issue and more.

Relief Therapeutics Reports Two Publications of Positive Data on Nexodyn(R) AOS for Hard-to-Heal Ulcers

GENEVA, SWITZERLAND / ACCESSWIRE / October 20, 2021 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB: RLFTF) (” Relief “), a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, today announced that its wholly owned subsidiary, APR Applied Pharma Research SA (” APR “), reported two papers published in the peer reviewed Journal of Wound Care , concluding that the company’s Nexodyn(R) acid-oxidizing solution (AOS), developed with APR’s proprietary Tehclo(R) technology, may represent a valuable therapeutic addition to standard of care (SOC) for the management of hard-to-heal ulcers requiring long periods of treatment. The data also confirmed the safety of Nexodyn(R) AOS.

Conducted by Elia Ricci, M.D., Director of the Difficult Wound Healing Unit, St. Luca Clinic, Department of Surgery A, Pecetto Torinese (TO), Piedmont, Italy, the prospective case series evaluated the clinical impact of Nexodyn(R) AOS in addition to SOC. Between February 2015 and February 2017, a total of 60 patients with hard-to-heal ulcers of various etiologies took part in the study. Patients were treated for 70 days with Nexodyn(R) AOS and the usual SOC wound dressings. The follow-up study, also conducted by Dr. Ricci, included a subset of 31 patients (51.7%) whose wounds had not fully healed by day 70, who opted to continue with treatment for another 22 weeks (for a total treatment time of 32 weeks) … read more

As an Active Cleanser, Nexodyn(R) AOS Shows Superior Wound Healing Performance Compared to Standard of Care

Relief’s Subsidiary, APR Applied Pharma Research, Reports Data Published in Journal of Wound Care, Indicating Nexodyn(R) AOS Highly Effective Treatment to Support Healing of Hard-to-Heal Leg Ulcers … RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF) (“Relief”), a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, today announced that its wholly owned subsidiary, APR Applied Pharma Research SA (“APR”), reported data published in the peer reviewed Journal of Wound Care, indicating that the company’s Nexodyn(R) acid-oxidizing solution (AOS), developed with APR’s proprietary Tehclo(R) technology, was found to be a highly effective treatment to support wound healing in infected or non-infected hard-to-heal leg ulcers. The data also confirmed the safety and tolerability of Nexodyn(R) … Conducted by Robert Strohal, M.D., Professor and Department Head, Department of Dermatology, Federal Academic Teaching Hospital of Feldkirch, Austria, and colleagues, the open-label, randomized controlled MACAN study was conducted at two centers is Austria. A total of 50 patients were enrolled, with either infected or non-infected hard-to-heal leg ulcers of different etiology. Patients were treated for six weeks either with Nexodyn(R) AOS or standard of care (SOC) wound dressings … In the patient group treated with Nexodyn(R) AOS, wounds exhibited a faster and more pronounced wound size reduction compared with wounds in the SOC group. Additionally, compared to SOC, the treatment group showed a markedly greater percentage of complete healing of hard-to-heal ulcers by the end of the study period (32% versus 8%, respectively). Furthermore, Nexodyn(R) demonstrated its ability to significantly reduce the wound pH (p<0.0001) and thus promote a faster healing process. In all patients with infected leg ulcers, local infection was overcome more rapidly with Nexodyn(R) AOS treatment. Overall, the efficacy of Nexodyn(R) AOS was found to be not only non-inferior but superior to SOC wound dressings … read more